Deepti H. Radia

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Journal: The Journal of allergy and clinical immunology

Published: December 16, 2025

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Journal: Leukemia

Published: November 06, 2025

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

Journal: The journal of allergy and clinical immunology. In practice

Published: July 07, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Journal: Haematologica

Published: June 20, 2025

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Journal: Leukemia

Published: June 19, 2025

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Journal: British journal of haematology

Published: May 07, 2025

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: April 25, 2025

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Journal: Leukemia research

Published: April 18, 2025

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal: Journal of the American Academy of Dermatology

Published: March 24, 2025

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

Journal: Leukemia

Published: March 19, 2025

Showing 1-12 of 96

Last Updated: 09/26/2026